title: Pharmacokinetics of zidovudine and lamivudine during oral uridine supplementation with NucleomaxX.
authors.forename: Nils
authors.initials: N
authors.lastname: Venhoff
authors.forename: Ana C
authors.initials: AC
authors.lastname: Venhoff
authors.forename: Anura L
authors.initials: AL
authors.lastname: Jayewardene
authors.forename: Fran
authors.initials: F
authors.lastname: Aweeka
authors.forename: Dirk
authors.initials: D
authors.lastname: Lebrecht
authors.forename: Ulrich A
authors.initials: UA
authors.lastname: Walker
mesh_terms: D000284:Administration, Oral; D019540:Area Under Curve; D004311:Double-Blind Method; D005260:Female; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008297:Male; D010919:Placebos; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D014529:Uridine / Q000008:administration & dosage*; D015215:Zidovudine / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use
chemical_list: D010919:Placebos; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D015215:Zidovudine; D014529:Uridine